Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Megace ES
- Development stage
- Unknown
- Lead developer
- Par Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Megace ES (megestrol acetate) is an oral suspension formulation developed by Par Pharmaceutical that utilizes nanocrystal technology to enhance the bioavailability of megestrol acetate, a synthetic derivative of the steroid hormone progesterone. This 'Enhanced Solubility' (ES) version allows for a significantly lower volume of administration compared to the original Megace suspension. It is primarily indicated for the treatment of anorexia, cachexia, or unexplained significant weight loss in patients with acquired immunodeficiency syndrome (AIDS). Megestrol acetate acts as an appetite stimulant, likely through its activity as a progesterone receptor agonist and its ability to modulate hypothalamic neuropeptides (such as neuropeptide Y) and suppress pro-inflammatory cytokines like IL-1, IL-6, and TNF-alpha. It also possesses antineoplastic properties and is used in the management of advanced breast and endometrial cancers.
- Brand names
- Megace ESMegace
- Other names
- megestrol acetatetislelizumab + cisplatin + gemcitabine + trilaciclib-Par Pharmaceutical, Inc.-anorexia-cachexia
02
Targets
GR (Glucocorticoid receptor)PR (Progesterone receptor)AR (Adrenergic receptors)
Beyond the preview
Go deeper on Megace ES.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Megace ES.